Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company is involved in developing PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases; PRS-332, a bispecific anticalin-antibody fusion protein that is in preclinical evaluation stage for oncology diseases; PRS-080 that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; and PRS-060, a drug candidate, which is in Phase I clinical trial that binds to the IL- 4Ra receptor for the treatment of asthma and other inflammatory diseases, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc., as well as others; and non-strategic license or option agreements with Aska Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc., Sanofi Group, Allergan Sales, LLC, Allergan, Inc., and Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company, as well as license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone857-246-8998
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$25.27 million
Profitability
Miscellaneous
Employees68
Next Earnings Date3/8/2019 (Estimated)
OptionableOptionable
Pieris Pharmaceuticals (NASDAQ:PIRS) Frequently Asked Questions
What is Pieris Pharmaceuticals' stock symbol?
Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."
How were Pieris Pharmaceuticals' earnings last quarter?
Pieris Pharmaceuticals Inc (NASDAQ:PIRS) posted its quarterly earnings data on Thursday, August, 9th. The biotechnology company reported $0.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by $0.01. The biotechnology company had revenue of $11.69 million for the quarter, compared to analyst estimates of $13.46 million. Pieris Pharmaceuticals had a negative return on equity of 18.07% and a negative net margin of 17.90%. View Pieris Pharmaceuticals' Earnings History.
When is Pieris Pharmaceuticals' next earnings date?
What price target have analysts set for PIRS?
4 Wall Street analysts have issued twelve-month price objectives for Pieris Pharmaceuticals' stock. Their predictions range from $5.00 to $13.00. On average, they expect Pieris Pharmaceuticals' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 224.7% from the stock's current price. View Analyst Price Targets for Pieris Pharmaceuticals.
What is the consensus analysts' recommendation for Pieris Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pieris Pharmaceuticals.
Has Pieris Pharmaceuticals been receiving favorable news coverage?
News headlines about PIRS stock have been trending somewhat positive on Saturday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Pieris Pharmaceuticals earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days.
Who are some of Pieris Pharmaceuticals' key competitors?
Some companies that are related to Pieris Pharmaceuticals include Eloxx Pharmaceuticals (ELOX), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Senomyx (SNMX), Dyadic International (DYAI), HedgePath Pharmaceuticals (HPPI), BIOQUAL (BIOQ), Vitality Biopharma (VBIO), Bioanalytical Systems (BASI), Cleveland BioLabs (CBLI), US Stem Cell (USRM), Geovax Labs (GOVX) and Protalex (PRTX).
What other stocks do shareholders of Pieris Pharmaceuticals own?
Who are Pieris Pharmaceuticals' key executives?
Pieris Pharmaceuticals' management team includes the folowing people:
- Mr. Stephen S. Yoder, CEO, Pres & Director (Age 43)
- Dr. Allan Reine, Sr. VP, CFO & Treasurer (Age 44)
- Dr. Louis A. Matis, Sr. VP & Chief Devel. Officer (Age 68)
- Mr. Claus Schalper, Co-Founder & Sr. Advisor
- Maria Kelman, Director of Investor Relations
Who are Pieris Pharmaceuticals' major shareholders?
Pieris Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Acadian Asset Management LLC (4.13%), Nantahala Capital Management LLC (2.51%), Millennium Management LLC (1.70%), Assenagon Asset Management S.A. (1.42%), Sphera Funds Management LTD. (1.29%) and Northern Trust Corp (0.85%). Company insiders that own Pieris Pharmaceuticals stock include Allan Reine, Christopher P Kiritsy, James A Geraghty and Orbimed Advisors Llc. View Institutional Ownership Trends for Pieris Pharmaceuticals.
Which institutional investors are selling Pieris Pharmaceuticals stock?
PIRS stock was sold by a variety of institutional investors in the last quarter, including Prosight Management LP, Millennium Management LLC, GSA Capital Partners LLP, Sphera Funds Management LTD., Los Angeles Capital Management & Equity Research Inc., Northern Trust Corp and Geode Capital Management LLC. View Insider Buying and Selling for Pieris Pharmaceuticals.
Which institutional investors are buying Pieris Pharmaceuticals stock?
PIRS stock was acquired by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, Assenagon Asset Management S.A., RBF Capital LLC, Bank of America Corp DE, Fosun International Ltd, Wedge Capital Management L L P NC, 683 Capital Management LLC and Dimensional Fund Advisors LP. Company insiders that have bought Pieris Pharmaceuticals stock in the last two years include Allan Reine, Christopher P Kiritsy and James A Geraghty. View Insider Buying and Selling for Pieris Pharmaceuticals.
How do I buy shares of Pieris Pharmaceuticals?
Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pieris Pharmaceuticals' stock price today?
One share of PIRS stock can currently be purchased for approximately $3.08.
How big of a company is Pieris Pharmaceuticals?
Pieris Pharmaceuticals has a market capitalization of $166.78 million and generates $25.27 million in revenue each year. The biotechnology company earns $-17,640,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Pieris Pharmaceuticals employs 68 workers across the globe.
What is Pieris Pharmaceuticals' official website?
How can I contact Pieris Pharmaceuticals?
Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected]
MarketBeat Community Rating for Pieris Pharmaceuticals (NASDAQ PIRS)
MarketBeat's community ratings are surveys of what our community members think about Pieris Pharmaceuticals and other stocks. Vote "Outperform" if you believe PIRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PIRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
